New Diagnostic Tool for Metastatic Prostate Cancer Advances Following License Agreement

New Diagnostic Tool for Metastatic Prostate Cancer Advances Following License Agreement
The development of CTT1057, a new product for the diagnosis of metastatic prostate cancer, received a boost with the worldwide license agreement between Novartis-held company Advanced Accelerator Applications (AAA) and Cancer Targeted Technology (CTT). Men with prostate cancer typically show elevated blood levels of prostate-specific antigen (PSA). Screening for PSA levels is common in men who have no symptoms, as well as in those with an already confirmed diagnosis of prostate cancer. But PSA is not accurate enough to diagnose prostate cancer, and better methods are needed. F-18 labeled CTT1057 is a peptide product developed by CTT. Now AAA will work on its continued development and commercialization if it is approved. The investigational compound specifically binds to the prostate-specific membrane antigen (PSMA) and was designed for prostate cancer imaging with positron emission tomography (PET), a method that uses a radioactive tracer to reveal the functioning of tissues and organs. Upon binding to PSMA, CTT1057 is internalized and accumulates inside tumor cells. PET imaging with molecules that bind to PSMA improves the detection of metastatic lesions, even with low blood PSA levels in patients with disease recurrence. “This agreement expands our position in the important prostate cancer space,” Susanne Schaffert, PhD, chairperson and president of AAA, said in a
Subscribe or to access all post and page content.